Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
5380- ART/DHA,    Artemisinin and Its Derivatives as Potential Anticancer Agents
- Review, Var, NA
TumCG↓, angioG↓, Ferroptosis↑, TumCP↑, TumAuto↑, CSCs↑, eff↑, YAP/TEAD↓, TumCCA↑, ROS↑, ChemoSen↑, N-cadherin↓, Vim↓, MMP9↓, eff↑, STAT3↓, CD133↓, CD44↓, Nanog↓, cMyc↓, OCT4↓, Akt↓, mTOR↓,
5379- ART/DHA,    Iron-fueled ferroptosis: a new axis for immunomodulation to overcome cancer drug resistance—from immune microenvironment crosstalk to therapeutic translation
Ferritin↓, Iron↑, Fenton↑, lipid-P↑, ChemoSen↑, ROS↑, eff↝,
5378- ART/DHA,    Natural Agents Modulating Ferroptosis in Cancer: Molecular Pathways and Therapeutic Perspectives
- Review, Var, NA
Ferroptosis↑, Iron↑, lipid-P↑, MOMP↑, AntiCan↑, NCOA4↑, GSH↓, GPx4↓, ROS↑, ChemoSen↑, ER Stress↑, DNAdam↑, angioG↓, TumCCA↑, eff↓,
5377- ART/DHA,    Dihydroartemisinin-induced ferroptosis in acute myeloid leukemia: links to iron metabolism and metallothionein
- in-vitro, AML, NA
AntiCan↑, Ferroptosis↑, Iron↑, Mets↑, eff↑, GSH↝, eff↑, other↓, eff↑, other↓,
5376- ART/DHA,    Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29 - in-vitro, CRC, SW48 - in-vitro, BC, MDA-MB-453
Ferroptosis↑, Ferritin↓, Iron↑, eff↑, TumAuto↑, LC3II↑, ROS↑,
4278- ART/DHA,    Artemisinin Ameliorates the Neurotoxic Effect of 3-Nitropropionic Acid: A Possible Involvement of the ERK/BDNF/Nrf2/HO-1 Signaling Pathway
- in-vivo, NA, NA
*IL6↓, *Casp3↓, *Casp9↓, *BDNF↑, *ERK↑, *NRF2↑, *HO-1↑, *neuroP↑, *antiOx↑, *Inflam↓,
5129- ART/DHA,    Evidence for the Involvement of Carbon-centered Radicals in the Induction of Apoptotic Cell Death by Artemisinin Compounds
- in-vitro, AML, HL-60
Casp↑, Apoptosis↑, MMP↓, TumCCA↑, eff↑, eff↑,
5137- ART/DHA,    Autophagy-dependent cell cycle arrest in esophageal cancer cells exposed to dihydroartemisinin
- vitro+vivo, ESCC, Eca109
tumCV↓, TumCCA↑, ROS↑, TumAuto↑, eff↓, TRF2↓, TumCP↓,
5136- ART/DHA,    Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis
- in-vitro, Var, NA
angioG↓, TumCP↓, TumCMig↓, NF-kB↓,
5135- ART/DHA,    Dihydroartemisinin Inhibits mTORC1 Signaling by Activating the AMPK Pathway in Rhabdomyosarcoma Tumor Cells
- vitro+vivo, Var, NA
mTORC1↓, AMPK↑, TumCG↓,
5134- ART/DHA,    Dihydroartemisinin induces autophagy by suppressing NF-κB activation
- in-vitro, Var, NA
TumAuto↑, NF-kB↓, ChemoSen↑,
5133- ART/DHA,    Dihydroartemisinin Exerts Anti-Tumor Activity by Inducing Mitochondrion and Endoplasmic Reticulum Apoptosis and Autophagic Cell Death in Human Glioblastoma Cells
- in-vitro, GBM, U87MG - in-vitro, GBM, U251
AntiTum↑, tumCV↓, Apoptosis↓, MMP↓, Cyt‑c↑, Casp9↑, CHOP↑, GRP78/BiP↑, eIF2α↑, Casp12↑, ER Stress↑, TumAuto↑, ROS↑,
5132- ART/DHA,    Dihydroartemisinin Exerts Its Anticancer Activity through Depleting Cellular Iron via Transferrin Receptor-1
- in-vitro, Liver, HepG2 - in-vitro, BC, MCF-7
Iron↓, TfR1/CD71↓, ROS↑,
5131- ART/DHA,    Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells
- in-vitro, NSCLC, ASTC-a-1
Apoptosis↑, MMP↓, Casp3↑, TumCP↓,
5130- ART/DHA,    Dihydroartemisinin Induces Apoptosis in Human Bladder Cancer Cell Lines Through Reactive Oxygen Species, Mitochondrial Membrane Potential, and Cytochrome C Pathway
- in-vitro, Bladder, T24/HTB-9
tumCV↓, eff↓, Apoptosis↑, Casp3↑, ROS↑, Cyt‑c↑, MMP↓, Bcl-2↓, BAX↑, MOMP↑, TumCG↓,
4991- ART/DHA,  doxoR,    Dihydroartemisinin alleviates doxorubicin-induced cardiotoxicity and ferroptosis by activating Nrf2 and regulating autophagy
- in-vivo, Nor, H9c2
*cardioP↑, *ROS↓, *Ferroptosis↓, *NRF2↑, Keap1↓,
4992- ART/DHA,    Dihydroartemisinin Increases the Sensitivity of Acute Myeloid Leukemia Cells to Cytarabine via the Nrf2/HO-1 Anti-Oxidant Signaling Pathway
- in-vitro, AML, HL-60
Apoptosis↑, Diff↑, ROS↓, HO-1↓, NRF2∅,
4993- ART/DHA,    Dihydroartemisinin inhibits galectin-1–induced ferroptosis resistance and peritoneal metastasis of gastric cancer via the Nrf2–HO-1 pathway
- vitro+vivo, GC, NA
Ferroptosis↑, NRF2↓, HO-1↓, PI3K↓, Akt↓, TumMeta↓,
1147- ART/DHA,    Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1
- vitro+vivo, Ovarian, HO-8910 - vitro+vivo, Nor, HUVECs
angioG↓, TumCG↓, VEGF↓, KDR/FLK-1↓, *toxicity↓,
1148- ART/DHA,    Artemisinin inhibits extracellular matrix metalloproteinase inducer (EMMPRIN) and matrix metalloproteinase-9 expression via a protein kinase Cδ/p38/extracellular signal-regulated kinase pathway in phorbol myristate acetate-induced THP-1 macrophages
- in-vitro, AML, THP1
MMP9↓, EMMPRIN↓, p‑PKCδ↓, p‑JNK↓, p‑p38↓, p‑ERK↓,
2323- ART/DHA,    Dihydroartemisinin represses esophageal cancer glycolysis by down-regulating pyruvate kinase M2
- in-vitro, ESCC, Eca109 - in-vitro, ESCC, EC9706
PKM2↓, lactateProd↓, GlucoseCon↓, cycD1/CCND1↓, Bcl-2↓, MMP2↓, VEGF↓, Casp3↑, cl‑PARP↑, BAX↑, DNAdam↑, ROS↑,
2322- ART/DHA,    Dihydroartemisinin Regulates Self-Renewal of Human Melanoma-Initiating Cells by Targeting PKM2/LDHARelated Glycolysis
- in-vitro, Melanoma, NA
TumCP↓, PKM2↓, LDHA↓, Glycolysis↓,
2321- ART/DHA,    Dihydroartemisinin mediating PKM2-caspase-8/3-GSDME axis for pyroptosis in esophageal squamous cell carcinoma
- in-vitro, ESCC, Eca109 - in-vitro, ESCC, EC9706
Pyro↑, PKM2↓, Casp8↑, Casp3↑, Warburg↓, TumCCA↑, Apoptosis↑,
2320- ART/DHA,    Dihydroartemisinin Inhibits the Proliferation of Leukemia Cells K562 by Suppressing PKM2 and GLUT1 Mediated Aerobic Glycolysis
- in-vitro, AML, K562 - in-vitro, Liver, HepG2
Glycolysis↓, GlucoseCon↓, lactateProd↓, GLUT1↓, PKM2↓, ECAR↓, LDHA↓, cMyc↓, other↝,
2324- ART/DHA,    Research Progress of Warburg Effect in Hepatocellular Carcinoma
- Review, Var, NA
PKM2↓, GLUT1↓, Glycolysis↓, Akt↓, mTOR↓, Hif1a↓, HK2↓, LDH↓, NF-kB↓,
2569- ART/DHA,    A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction
- Human, Nor, NA
*Half-Life↝, BioAv↝, *Half-Life↓, BioAv↑, *Dose↝,
2570- ART/DHA,    Discovery, mechanisms of action and combination therapy of artemisinin
- Review, Nor, NA
*BioAv↓, *Half-Life↓, *toxicity↓, *ROS↑, GSH↓, selectivity↑,
2575- ART/DHA,  docx,    Artemisia santolinifolia-Mediated Chemosensitization via Activation of Distinct Cell Death Modes and Suppression of STAT3/Survivin-Signaling Pathways in NSCLC
- in-vitro, Lung, H23
ChemoSen↑, GPx4↓, ROS↑, Ferroptosis↑, eff↑,
2571- ART/DHA,    Cancer combination therapies with artemisinin-type drugs
- Review, Var, NA
AntiTum↑, ChemoSen↑, hepatoP↝,
2572- ART/DHA,  SRF,    Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax
- in-vitro, AML, NA
CHOP↑, Mcl-1↓, ChemoSen↑, selectivity↑,
2573- ART/DHA,    Cell death mechanisms induced by synergistic effects of halofuginone and artemisinin in colorectal cancer cells
- in-vitro, CRC, HCT116
eff↑,
2574- ART/DHA,    Artemisinin: A Promising Adjunct for Cancer Therapy
- Review, Var, NA
selectivity↑, eff↑,
2576- ART/DHA,  AL,    The Synergistic Anticancer Effect of Artesunate Combined with Allicin in Osteosarcoma Cell Line in Vitro and in Vivo
- in-vitro, OS, MG63 - in-vivo, NA, NA
eff↑, tumCV↓, Casp3↑, Casp9↑, Apoptosis↑, TumCG↓,
2577- ART/DHA,    Artemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectives
- Review, Var, NA
eff↑, TumCCA↑, BioAv↑, eff↑, ChemoSen↑,
2578- ART/DHA,  RES,    Synergic effects of artemisinin and resveratrol in cancer cells
- in-vitro, Liver, HepG2 - in-vitro, Cerv, HeLa
Dose↝, TumCMig↓, Apoptosis↑, necrosis↑, ROS↑, eff↑,
2580- ART/DHA,  VitC,    Effects of Antioxidants and Pro-oxidants on Cytotoxicity of Dihydroartemisinin to Molt-4 Human Leukemia Cells
- in-vitro, AML, NA
eff↓, other↝, ROS↑, eff↓, eff↓,
2581- ART/DHA,  PB,    Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells
- in-vitro, AML, NA
eff↑, selectivity↑,
2582- ART/DHA,  5-ALA,    Mechanistic Investigation of the Specific Anticancer Property of Artemisinin and Its Combination with Aminolevulinic Acid for Enhanced Anticolorectal Cancer Activity
- in-vivo, CRC, HCT116 - in-vitro, CRC, HCT116
eff↑, ROS↑, selectivity↑, TumCG↓, toxicity↓,
2461- ASA,    Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis
- Review, NA, NA
AntiAg↑, COX1↓, eff↑,
5403- ASA,    Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer
- Trial, CRC, NA
Risk↓, other↝,
5416- ASA,    Cancer Incidence and Mortality With Aspirin in Older Adults
- Trial, Var, NA
Risk∅, OS∅,
5415- ASA,    The Anti-Metastatic Role of Aspirin in Cancer: A Systematic Review
- Review, Var, NA
TumMeta↓, COX1↓, TXA2↓, AntiAg↑, EMT↓, TumCMig↓, TumCI↓, AMPK↑, cMyc↓, PGE2↓, Dose↑, RadioS↑, PD-L1↓, E-cadherin↑, EMT↓, Slug↓, Vim↓, Twist↓, MMP2↓, MMP9↓, other↑,
5414- ASA,    Aspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against
- Review, Var, NA
Risk↓, *toxicity↓, other↑, *COX1↓, TumCP↓, DNArepair↑, ChemoSen↑, other↓,
5413- ASA,    Drug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating Aspirin
- Trial, Nor, NA
*cardioP↑, *other↝, *COX1↓, *TXA2↓,
5412- ASA,    Clinical Pharmacology of Aspirin
- Review, NA, NA
*COX1↓, *COX2↓, *cardioP↑, *BioAv↑, *BioAv↝, *Half-Life↓, Risk↓, *other↑, *AntiAg↑,
5411- ASA,    Mechanistic Insights into a Classic Wonder Drug—Aspirin
- Review, Var, NA
*COX2↓, *COX1↓, *Inflam↓, *cardioP↑, Risk↓,
5410- ASA,    Low-Dose Aspirin and the Prevention of Colorectal Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study
- Study, CRC, NA
Risk↓, Dose↝, Risk↓,
5408- ASA,    An aspirin a day keeps cancer at bay
- Review, Var, NA
TumMeta↓, TXA2↓, *AntiAg↑, COX1↓,
5400- ASA,    Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention
- Review, Nor, NA
Risk↓, *Inflam↓, *COX1↓, *AntiAg↑, *Half-Life↓, *BioAv↑,
5401- ASA,    Residual cyclooxygenase activity of aspirin-acetylated COX-2 forms 15R-prostaglandins that inhibit platelet aggregation
- Review, Nor, NA
*AntiAg↑, *COX1↓,

Showing Research Papers: 851 to 900 of 6604
Prev Page 18 of 133 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6604

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Fenton↑, 1,   Ferroptosis↑, 6,   GPx4↓, 2,   GSH↓, 2,   GSH↝, 1,   HO-1↓, 2,   Iron↓, 1,   Iron↑, 4,   Keap1↓, 1,   lipid-P↑, 2,   Mets↑, 1,   NRF2↓, 1,   NRF2∅, 1,   ROS↓, 1,   ROS↑, 13,  

Metal & Cofactor Biology ⓘ

Ferritin↓, 2,   NCOA4↑, 1,   TfR1/CD71↓, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 4,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 2,   cMyc↓, 3,   ECAR↓, 1,   GlucoseCon↓, 2,   Glycolysis↓, 3,   HK2↓, 1,   lactateProd↓, 2,   LDH↓, 1,   LDHA↓, 2,   PKM2↓, 5,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 3,   Apoptosis↓, 1,   Apoptosis↑, 7,   BAX↑, 2,   Bcl-2↓, 2,   Casp↑, 1,   Casp12↑, 1,   Casp3↑, 5,   Casp8↑, 1,   Casp9↑, 2,   Cyt‑c↑, 2,   Ferroptosis↑, 6,   p‑JNK↓, 1,   Mcl-1↓, 1,   MOMP↑, 2,   necrosis↑, 1,   p‑p38↓, 1,   Pyro↑, 1,   YAP/TEAD↓, 1,  

Transcription & Epigenetics ⓘ

other↓, 3,   other↑, 2,   other↝, 3,   tumCV↓, 4,  

Protein Folding & ER Stress ⓘ

CHOP↑, 2,   eIF2α↑, 1,   ER Stress↑, 2,   GRP78/BiP↑, 1,  

Autophagy & Lysosomes ⓘ

LC3II↑, 1,   TumAuto↑, 5,  

DNA Damage & Repair ⓘ

DNAdam↑, 2,   DNArepair↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   TumCCA↑, 6,  

Proliferation, Differentiation & Cell State ⓘ

CD133↓, 1,   CD44↓, 1,   CSCs↑, 1,   Diff↑, 1,   EMT↓, 2,   p‑ERK↓, 1,   mTOR↓, 2,   mTORC1↓, 1,   Nanog↓, 1,   OCT4↓, 1,   PI3K↓, 1,   STAT3↓, 1,   TRF2↓, 1,   TumCG↓, 6,  

Migration ⓘ

AntiAg↑, 2,   E-cadherin↑, 1,   EMMPRIN↓, 1,   MMP2↓, 2,   MMP9↓, 3,   N-cadherin↓, 1,   p‑PKCδ↓, 1,   Slug↓, 1,   TumCI↓, 1,   TumCMig↓, 3,   TumCP↓, 5,   TumCP↑, 1,   TumMeta↓, 3,   Twist↓, 1,   Vim↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 4,   Hif1a↓, 1,   KDR/FLK-1↓, 1,   TXA2↓, 2,   VEGF↓, 2,  

Barriers & Transport ⓘ

GLUT1↓, 2,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 3,   NF-kB↓, 3,   PD-L1↓, 1,   PGE2↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 2,   BioAv↝, 1,   ChemoSen↑, 9,   Dose↑, 1,   Dose↝, 2,   eff↓, 6,   eff↑, 18,   eff↝, 1,   RadioS↑, 1,   selectivity↑, 5,  

Clinical Biomarkers ⓘ

Ferritin↓, 2,   LDH↓, 1,   PD-L1↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 2,   AntiTum↑, 2,   hepatoP↝, 1,   OS∅, 1,   Risk↓, 7,   Risk∅, 1,   toxicity↓, 1,  
Total Targets: 123

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Ferroptosis↓, 1,   HO-1↑, 1,   NRF2↑, 2,   ROS↓, 1,   ROS↑, 1,  

Cell Death ⓘ

Casp3↓, 1,   Casp9↓, 1,   Ferroptosis↓, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,   other↝, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↑, 1,  

Migration ⓘ

AntiAg↑, 4,  

Angiogenesis & Vasculature ⓘ

TXA2↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 6,   COX2↓, 2,   IL6↓, 1,   Inflam↓, 3,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 2,   BioAv↝, 1,   Dose↝, 1,   Half-Life↓, 4,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 4,   neuroP↑, 1,   toxicity↓, 3,  
Total Targets: 29

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page